Table 1.
Clinical Outcomes Report
| Authors | Treatment | Patient Population | Patient No. | Study Design | Clinical Success Rate | Median Time to Culture Clearance | Ceftaroline related-ADE Rate | Notes |
|---|---|---|---|---|---|---|---|---|
| Multiple Infections | ||||||||
| Ho, Cadena, Childs. 2012. [10] | CPT 600mg q8-12h | MRSA bacteremia and IE | 6 | Case series | 83.3% | 2 days | None reported | 1 bacteremia patient died due to comorbidities |
| Lin et al. 2012. [11] | CPT 600mg q8-12h | MRSA IE, pneumonia, bone and joint infections | 10 | Case series | 60% | 3 days | 60% | 2 patients died from comorbidities; 1 died due to poor source control; ADE: rash, CDI, eosinophilia |
| Polenakovik, Pleiman. 2013. [12] | CPT 600mg q8-12ha | MRSA bacteremia and IE | 31 | Retrospective review | 74.2% | 3.5 days | 12.9% | 2 patients died due to comorbidities; ADE: eosinophilia, rash, CDI |
| Fabre, Ferrada, Buckel. 2014. [13] | CPT 600mg q8h ± TMP-SMX 10-15mg/kg/dayd | MRSA bacteremia and IE | 29 | Retrospective review | 31% | 3 days | 3.4% | 7 patients were lost to follow-up; 1 patient died from septic emboli; ADE: rash |
| Casapao et al. 2014. [14] | CPT 600mg q8-12h | MRSA bacteremia subgroup | 241 | Retrospective review | 78.3% | Not reported | None reported | Higher rates of ADEs in patients treated off-label |
| CNS Infections | ||||||||
| Kuriakose, Rabbat, Gallagher. 2015. [15] | CPT 600mg q8h | VP-shunt related MRSA meningitis | 1 | Case report | 100% | Cleared upon shunt removal | None reported | — |
| Balouch, Bajwa, Hassoun. 2015. [16] | CPT 600mg q8h + RIF 300mg BID | MRSA meningitis | 1 | Case report | 100% | 1 day | None reported | Culture clearance based on blood cultures; CSF cultures not repeated |
| Bucheit, Collins, Joshi. 2014. [17] | CPT 600mg q12h | MRSA epidural abscess | 1 | Case report | 100% | 1 day | None reported | Clearance based on blood; abscess cultures not repeated |
| Nosocomial Pneumonia | ||||||||
| Kaye, Udeani, Cole. 2015. [18] | CPT ± concomitant antibiotics | MRSA nosocomial pneumonia | 12 HAP 7 VAP | Retrospective review | 58.3% 57.1% | Not reported | 3% | Death rates not reported specifically for MRSA; ADE: unspecified |
| Pasquale, Tan, Trienski. 2015. [19] | CPT 600mg q12h | MRSA nosocomial pneumonia | 10 | Case series | 60% | Not reported | None reported | 3 patients died due to comorbidities; 1 patient relapsed after 1 week off antibiotics |
| Combination Therapy | ||||||||
| Rose, Schulz, Andes. 2012. [23] | CPT 200mg q12h + DAP 6mg/kg q48h | S. aureus IE | 1 | Case report | 100% | 4 days | None reported | Patient died after culture clearance due to comorbidities |
| Baxi, Chan, Jain. 2015. [24] | CPT 400mg q12h + DAPb | S. aureus IE | 1 | Case report | 100% | 11 days | None reported | — |
| Sakoulas et al. 2014. [25] | CPT 200mg q12h-600mg q8h + DAPb | Staphylococcal bacteremia | 26 | Case series | 96% | 2 days | None reported | 1 patient died due to comorbidities |
| Cunha, Gran. 2015. [26] | CPT 600mg q12h + DAP 12mg/kg q24h | MRSA prosthetic-valve IE | 1 | Case report | 100% | 4 days | None reported | — |
| Sundragiri, Vallabhajosyula, Haddad. 2015. [27] | CPT + DAPc | MRSA IE | 1 | Case report | 0% | No clearance | None reported | Patient remained septic and died eventually died |
Abbreviations: CPT, ceftaroline; RIF, rifampicin; DAP, daptomycin.aConcomitant antimicrobials given including linezolid, DAP, gentamicin, RIF and tigecycline.bVariety of DAP doses were used.cDoses unspecified.dTwenty-three patients also received SMX-TMP and 2 received DAP.